Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449741) titled 'Phase I Study of HXN6005 in Adult Healthy Participants' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd

Condition: Healthy Volunteers (HV)

Intervention: Drug: HXN6005

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 27, 2026

Target Sample Size: 40

Countries of Recruitment: Australia

To know more, visit https://clinicaltrials.gov/study/NCT07449741

Published by HT Digita...